Cargando…

1289. Assessing the Safety and Efficacy with Prolonged Use of Tedizolid in Orthopedic Patients

BACKGROUND: Bone and joint infections (BJI) often require 4 to 6 weeks of treatment with oral or intravenous antimicrobials. To aid in achieving clinical cure, oral agents should be highly bioavailable, have a wide therapeutic index, and ideally penetrate bone tissue well. Data is available for line...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garza, Daniel E, Maguire, Christina, Binkley, Amanda, Weinstein, Erica J, Silibovsky, Randi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676829/ http://dx.doi.org/10.1093/ofid/ofad500.1128

Ejemplares similares

2421. Tedizolid Is Well-Tolerated Among Patients Receiving Prolonged Treatment Courses
por: Marini, Rachel V, et al.
Publicado: (2018)

306. Safety and Tolerability of Tedizolid as Oral Treatment for Bone and Joint Infections
por: Launer, Bryn, et al.
Publicado: (2018)

1289. Douching and Rectal Inflammation in Sexual Minority Men: Implications for HIV Acquisition
por: McGaugh, Angela, et al.
Publicado: (2019)

1096. Linezolid versus Tedizolid for the Treatment of Nontuberculous Mycobacteria in Solid Organ Transplant Recipients: An Assessment of Safety
por: Poon, Yi Kee, et al.
Publicado: (2020)

Characteristics of Tedizolid Non-susceptible Enterococcal Clinical Isolates
por: Dhand, Abhay, et al.
Publicado: (2017)

471. Safety and Efficacy of Oral and/or Intravenous Tedizolid Phosphate (TZD) in Adolescents with Acute Bacterial Skin and Skin Structure Tissue Infections (ABSSSI)
por: Bradley, John S, et al.
Publicado: (2019)

Prolonged tedizolid use in cutaneous non-tuberculous mycobacterial infection
por: Shaw, Timothy David, et al.
Publicado: (2021)

1627. Tedizolid is Well-tolerated Among Patients Receiving Prolonged Treatment Courses, Including Those Who are Intolerant of Alternative Agents
por: Smith, Brandon, et al.
Publicado: (2020)

Correction to Lancet Oncol 2018; 19: 1289–306
Publicado: (2018)

1289. Knowledge, Attitudes and Barriers of Pre-exposure Prophylaxis for HIV Infection Among Resident Physicians in Rural, Eastern North Carolina
por: Morrison, Arianne, et al.
Publicado: (2018)

1578. Rifampicin Reduces Tedizolid Concentrations When Co-Administered in Healthy Volunteers
por: Lee, Lawrence, et al.
Publicado: (2019)

1083. Clinical Efficacy of Tedizolid for the Treatment of Mycobacterium abscessus complex Infections in Solid Organ Transplant Recipients
por: Poon, Yi Kee, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Tedizolid
por: Iqbal, Khalid, et al.
Publicado: (2022)

1313. Determinants of Prosthetic Joint Infection According to Time Following Total Knee Arthroplasty: A Retrospective Cohort Study Among US Veterans
por: Weinstein, Erica J, et al.
Publicado: (2023)

1289. The Challenge of Treating Community-Associated Enterobacterales Infections in a Middle-Income Country: Data from SMART 2018-2019
por: Telles, João Paulo, et al.
Publicado: (2021)

Safety and tolerability of tedizolid as oral treatment for bone and joint infections
por: Miller, Loren G., et al.
Publicado: (2023)

2287. Real-world Use of Tedizolid Phosphate: A Case Series of Long-Term Tolerability
por: Morrisette, Taylor, et al.
Publicado: (2019)

1312. Incidence and Microbiology of Prosthetic Joint Infection According to Time Following Total Knee Arthroplasty: A Retrospective Cohort Study Among US Veterans
por: Weinstein, Erica J, et al.
Publicado: (2023)

The Florentine Archives in Transition: Government, Warfare and Communication (1289–1530 ca.)
por: Guidi, Andrea
Publicado: (2016)

Correction to Lancet Glob Health 2022; 10: e1289–97
Publicado: (2022)

1289. Pravibismane is a Potent, Broad Spectrum Anti-Infective Small Molecule that Rapidly Disrupts Bacterial Bioenergetics and Halts Bacterial Growth
por: Baker, Brett
Publicado: (2020)

Tolerance of Prolonged Oral Tedizolid for Prosthetic Joint Infections: Results of a Multicentre Prospective Study
por: Senneville, Eric, et al.
Publicado: (2020)

712. Identification of a Novel Tedizolid Resistance Mutation in rpoB of Methicillin-Resistant Staphylococcus aureus
por: Werth, Brian, et al.
Publicado: (2018)

miR-1289 and “Zipcode”-like Sequence Enrich mRNAs in Microvesicles
por: Bolukbasi, Mehmet Fatih, et al.
Publicado: (2012)

160. Antimicrobial Prescribing Patterns in Bloodstream Infections Caused by Cefepime-Susceptible Extended Spectrum β-lactamase Enterobacterales
por: O’Rourke, Emerald, et al.
Publicado: (2022)

In vitro Susceptibility of Nontuberculous Mycobacteria to Tedizolid
por: Zhang, Huiyun, et al.
Publicado: (2022)

2235. Characterization of the Adult Sepsis Treatment Guideline Utilization Within the Emergency Department at an Academic Medical Center
por: Berg, Deanna M, et al.
Publicado: (2023)

395. Safety and Tolerability of Rifampin in Staphylococcal Orthopedic Infections
por: Miller, Andy O, et al.
Publicado: (2019)

Tedizolid Phosphate: a Next-Generation Oxazolidinone
por: Rybak, Jeffrey M., et al.
Publicado: (2015)

Tedizolid: new data and experiences for clinical practice
por: Lletí, Miguel Salavert, et al.
Publicado: (2021)

Activity of Tedizolid against Gram-Positive Clinical Isolates Causing Nosocomial- and Community-Acquired Infections in United States Hospitals (2014–2016)
por: Mendes, Rodrigo E, et al.
Publicado: (2017)

1,9-Bis(2-pyridyl)-1,2,8,9-tetrathia-5-oxanonane
por: Kalia, Jeet, et al.
Publicado: (2009)

Run 1289 6/9/82, 3.5 GeV/c Ring 2
por: Baird, S
Publicado: (1982)

MicroRNA-1289 Functions as a Novel Tumor Suppressor in Oral Squamous Cell Carcinoma
por: Nakashiro, Koh-ichi, et al.
Publicado: (2023)

Intracellular activity of tedizolid phosphate and ACH-702 versus Mycobacterium tuberculosis infected macrophages
por: Molina-Torres, Carmen A, et al.
Publicado: (2014)

2841. A Phase 3, Randomized, Double-Blind Study Comparing Tedizolid Phosphate (TZD) and Linezolid (LZD) for Treatment of Ventilated Gram-Positive (G+) Nosocomial Pneumonia
por: Wunderink, Richard G, et al.
Publicado: (2019)

1397. Comparative Efficacy of Human-Simulated Epithelial Lining Fluid (ELF) Exposures of Tedizolid (TZD) Against Methicillin-resistant Staphylococcus Aureus (MRSA) in Neutropenic (I−) vs. Immunocompetent (I+) Murine Models of Pneumonia
por: Kidd, James M, et al.
Publicado: (2018)

Single- and Multiple-Dose Pharmacokinetics and Absolute Bioavailability of Tedizolid
por: Flanagan, Shawn, et al.
Publicado: (2014)

Effect of the human endotoxin challenge on tedizolid tissue penetration
por: Jorda, Anselm, et al.
Publicado: (2022)

Infection in Kidney Transplantation
por: Nambiar, Puja, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_pv2sq85ffe7scqu6h6p0871jrs